PainReform Ltd (PRFX) Actualités

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

TEL AVIV, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

This notification has no immediate effect on the listing or trading of PainReform’s ordinary shares on the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form EFFECT - Notice of Effectiveness

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form F-3 - Registration statement by foreign private issuers

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the...